Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management
American Journal of Hematology · 2024-08 · 99 (8) · 1586-1594
DOI: 10.1002/ajh.27376 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 20.05.2024. Verfasst von Andres Ramirez-Gamero und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Plasmablastic Lymphoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 78 Literaturangaben.
Abstract (Originalsprache)
Disease Overview Plasmablastic lymphoma (PBL) is a rare CD20‐negative aggressive lymphoma with a poor prognosis under standard treatment options. Though PBL is associated with human immunodeficiency virus infection and other immunosuppressed states, it can also affect immunocompetent individuals. Diagnosis The diagnosis requires a high clinical suspicion and pathological confirmation. EBER expression and MYC gene rearrangements are frequently detected. The differential diagnosis includes EBV+ diffuse large B‐cell lymphoma, extracavitary primary effusion lymphoma, ALK+ DLBCL, and HHV8+ large B‐cell lymphoma, among others. Risk Stratification Age ≥60 years, advanced clinical stage, and high intermediate and high International Prognostic Index scores are associated with worse survival. Management Combination chemotherapy regimens, such as EPOCH, are recommended. The addition of bortezomib, lenalidomide, or daratumumab might improve outcomes. Including PBL patients and their participation in prospective clinical trials is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Instituto Nacional de Cancerologia and Hospital Militar Central, Bogota, Colombia.
- Department of Oncology and Radiotherapy, Hospital Edgardo Rebagliati Martins and Instituto de Ciencias Biomedicas, Universidad Ricardo Palma, Lima, Peru.
- Division of Hematology and Oncology, University of North Carolina, Chapel Hill, North Carolina, USA.
- Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Andres Ramirez-Gamero, Humberto Martínez-Cordero, Brady E Beltrán, Jorge Florindez, Luis Malpica, Jorge J Castillo
Zitieren
APA
Ramirez-Gamero, A., Martínez-Cordero, H., Beltrán, B. E., Florindez, J., Malpica, L., & Castillo, J. J. (2024). Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. American Journal of Hematology, 99(8), 1586-1594. https://doi.org/10.1002/ajh.27376
Vancouver
Ramirez-Gamero A, Martínez-Cordero H, Beltrán BE, Florindez J, Malpica L, Castillo JJ. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. American Journal of Hematology. 2024;99(8):1586-1594. doi:10.1002/ajh.27376
BibTeX
@article{RamirezGamero2024,
author = {Ramirez-Gamero, Andres and Martínez-Cordero, Humberto and Beltrán, Brady E and Florindez, Jorge and Malpica, Luis and Castillo, Jorge J},
title = {Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {8},
pages = {1586--1594},
doi = {10.1002/ajh.27376}
}
EUVIMED